Abstract
Atopic dermatitis is an inflammatory skin condition characterised by pruritus and a chronic relapsing-remitting course. Previous topical and systemic treatments for atopic dermatitis were broadly immunosuppressive, which limited their long-term use. Recently, more targeted therapies for atopic dermatitis have been developed. In this review, we discuss the efficacy and safety of new therapies, including topical PDE4 (phosphodiesterase 4) inhibitors, a topical aryl hydrocarbon receptor agonist, topical and systemic JAK (Janus kinase) inhibitors and biologics.